1 / 10

Disclosure Statement of Financial Interest

Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME 2 trial.

kalona
Download Presentation

Disclosure Statement of Financial Interest

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME 2 trial William Fearon, Bernard De Bruyne, NicoPijls, David Shilane, Derek Boothroyd, PimTonino, EmmanueleBarbato, Peter Juni, and Mark Hlatky on behalf of the FAME 2 Trial Investigators

  2. Disclosure Statement of Financial Interest Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity Royalty Income Ownership/Founder Intellectual Property Rights Other Financial Benefit St. Jude Medical, NIH HeartFlow Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company FAME 2 was sponsored by St. Jude Medical

  3. Fractional Flow Reserve Proximal Pressure (Pa) Distal Pressure (Pd) FFR = Pd / Pa during maximal flow Pa Pd / Pa = 60 / 100 FFR = 0.60 Pd

  4. FAME 2 Trial Stable patients with 1, 2, or 3 vessel CAD evaluated for PCI with DES n=1220 FFR in all target lesions Registry Randomized Trial At least 1 stenosis with FFR ≤ 0.80 (n=888) All FFR > 0.80 (n=322) Randomization 1:1 MT MT PCI + MT 50% randomly assigned to follow-up Primary Endpoint: Death, MI, Urgent Revascularization at 2 years

  5. FAME 2 Trial Results % De Bruyne, et al. New Engl J Med 2012;367:991-1001.

  6. Results Quality of Life at 1 Month

  7. Cumulative Costs over 12 Months $2,508 $5,485 % of study population 100% 56% 11%

  8. FFR-Guided PCI Cost-Effectiveness In-trial results $2,500 / 0.047 QALY = $53,000 / QALY Three Year Projection $2,500 / 0.079 QALY = $32,000 / QALY

  9. Cost-Effectiveness CE Benchmarks: Hemodialysis ≈ $50,000 / QALY WHO GDP std ≈ $150,000 / QALY >$150,000 / QALY $50K-150K / QALY <$50,000 / QALY

  10. Conclusion: • FFR-Guided PCI has higher initial cost than medical therapy. • The cost gap narrows >50% by one year. • Angina and quality of life are significantly improved by PCI. • FFR-Guided PCI appears to be economically attractive in cost-effectiveness analysis

More Related